Emerging Growth Research Reiterates Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Q4:25 Quarterly Update

Finviz2026/04/06 20:03

By:Finviz

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

NEW YORK CITY, NY / ACCESS Newswire / April 6, 2026 / Emerging Growth Research today announced the release of its Quarterly Update Report on SBC Medical Group Holdings, Inc. (Nasdaq:SBC), reiterating a Buy-Extended rating and maintaining its 12-month price target of $9.00, representing potential upside from the Company's closing price of $4.47 on April 3, 2026.

The Quarterly Update reflects SBC's Q4:25 financial results, ongoing business transition, and outlook for a return to revenue growth in 2026 following pricing-related headwinds experienced during 2025.

Key Highlights from the Quarterly Update Report:

Revenue Pressure with Expected Recovery: Q4:25 revenue declined year-over-year to approximately $39.6 million, primarily reflecting the impact of changes to the Company's franchise fee structure implemented earlier in 2025. Management expects revenue trends to stabilize with a return to modest growth in 2026.

Profitability Improvement: Operating income and net income increased significantly year-over-year, largely due to the absence of prior-period non-recurring charges. Sequential profitability remained relatively stable despite lower revenue levels.

Strong Cash Position: SBC continues to maintain a substantial cash balance of approximately $164 million with relatively low debt, providing flexibility to support ongoing operations and potential strategic initiatives.

Underlying Volume Growth: Despite pricing pressure, underlying business fundamentals remain stable, with total customer visits increasing to approximately 6.6 million annually and a repeat rate of roughly 72%. The Company expanded its clinic network to 283 locations.

Business Transition and Strategy: The Company continues to adjust to pricing changes implemented in 2025, while focusing on operational efficiency and long-term growth initiatives, including international expansion and new offerings such as AI-driven operational improvements and longevity-focused services.

Valuation and Outlook: The report notes that SBC's shares remain discounted relative to historical performance and internal valuation frameworks. Emerging Growth Research expects a gradual recovery in revenue growth in 2026, followed by a potential return to longer-term growth trends supported by both organic expansion and selective M&A activity.

According to Emerging Growth Research, SBC has navigated a period of near-term pricing and competitive pressure while maintaining profitability and a strong balance sheet. The Company is now positioned to focus on stabilizing revenue and pursuing longer-term growth opportunities across both domestic and international markets.

About SBC Medical Group Holdings, Inc.

SBC Medical Group Holdings, Inc. (Nasdaq:SBC) provides management services to cosmetic treatment centers through a franchise model. The Company operates across multiple healthcare service areas, including dermatology and aesthetic treatments, with a primary presence in Japan and expanding operations in Southeast Asia and the United States.

Contact:

Emerging Growth Research

Forward-Looking Statements

This press release contains forward-looking statements concerning business operations, financial performance, and future expectations of SBC Medical Group Holdings, Inc. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

Emerging Growth Research Reiterates Buy-Extended Rating on SBC Medical Group Holdings, Inc. with $9.00 Price Target Following Q4:25 Quarterly Update image 0

SOURCE: SBC Medical Group Holdings Incorporated

View the original press release on ACCESS Newswire

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

1. The sharp escalation in Middle East tensions pushed Brent crude to multi-year highs of $105–$107 per barrel, reviving inflation expectations. The 10-year U.S. Treasury yield surged to 4.94%, its highest level since 2023, while the implied probability of a rate hike at the September 16 policy meeting to the 3.75%–4.00% range rose from 48.4% one month ago to 67.1%. 2. Rising oil prices and rate-hike expectations weighed on most risk assets, but historical data suggest that this is more likely to be a short-term adjustment than a reversal of the broader trend. Bitcoin fell 3.36% this week and the S&P 500 declined 1.64%, while gold slipped just 0.96%. Outside the energy sector, markets are largely repricing ahead of next week's expected rate decision. 3. PoolX has recently introduced a long-term holding bonus, significantly improving effective returns for users who maintain assets on the platform over time. The core participation rules remain unchanged; the update adds an additional boost to the effective locked amount for users with qualifying long-term holdings. In the example provided, a user locking 1000 ETH would see the estimated reward increase from 1666.67 USDT to 2500 USDT, or about 50%, while the reference APR rises from 4.93% to 7.40%. Assets to watch: BTC, ETH, SOL, Brent crude, WTI crude, gold, 10-year U.S. Treasuries, RAY, ZEC, LEN, CCL.

Bitget•2026/09/14 08:10